Endocrine Abstracts

There is an association between high LDL-Ch levels and cardiovascular disease in T2DM patients. Clinical trials have shown that reduction of LDL-Ch with statins has a beneficial effect on macrovascular complications in patients with T2DM, but is this a relevant effect in clinical practice? LAF has a slower absorption, longer action time and less side effects than other statins.Objective: To assess in clinical practice, the effect of LAF on LDL-Ch and the...

Lipoadenoma is an uncommon benign lesión of the parathyroid gland (<1%) and it has most commonly described as non-functional, but also is a very rare cause of primary hyperparathyroidism. Since 1958 scientific literatura had described 54 cases all over the world and only six of that paratyroid lipoadenomas was extended into torax. A case of intrathoracic parathyroid lipoadenoma with hyperparathyroidism is described. A 69–year–old man was refered to our hos...

Prostate cancer (PCa) is one of the leading causes of cancer deaths among men population worldwide. This tumour pathology is commonly diagnosed through the determination of serum PSA levels. However, the diagnostic capability of PSA dramatically drops when considering patients with PSA levels lower than 10 ng/ml, the so-called “grey-zone”1. Therefore, additional non-invasive diagnostic biomarkers are urgently needed to substitute/complement PSA. In this se...

Introduction: The autoimmune polyglandular syndrome is a complex, heterogeneous disease in which autoimmune diseases of endocrine and non-endocrine organs can occur. There are 4 subgroups: the early-onset APS I develops due to the mutation of the gene AIRE and characterized by the presence of Addison’s disease (AD), mucocutan candidiasis and hypoparathyroidism; the APS II is defined by the appearance of AD and autoimmune thyroid diseases (AITDs) and/or diabetes mellitus; ...

Introduction: Both cortisol and vasopressin are stress hormones. Earlier, our group demonstrated that serum concentrations of free cortisol at admissions to the Intensive Care Unit (ICU) were independent predictors of survival in critically ill patients. Other investigators have demonstrated that serum copeptin, a surrogate marker of vasopressin may also be a predictive factor in this patient population. The aim of our present study was to compare the prognostic roles of serum...

Introduction: The autoimmune polyglandular syndrome (APS) is a complex, heterogeneous condition in which autoimmune diseases (AIs) of endocrine and non-endocrine organs can occur. There are four subgroups. The majority of patients are categorized as having APS II or APS III. In APS II, patients have Addison’s disease (AD) and autoimmune thyroid diseases (AITDs) or type I. diabetes mellitus (T1DM), while in the APS III, AITDs are combined with other autoimmune illnesses ex...

Background: AMH represents a marker of ovarian reserve and is used in monitoring the effects of gonadotoxic drugs. In PCOS is higher and is an indirect marker of hyperandrogenism. In transsexual man(TM), high prevalence of PCOS is described and AMH provide information about ovarian reserve after exposure to testosterone.Objective: To assess the prevalence of PCOS in young TM previously to testosterone treatment, study the evolution of AMH levels and diff...

Background: There is evidence that dietary interventions can reduce antibody levels in patients with autoimmune thyroid disease (ATD), which can have a beneficial effect on the clinical manifestations of the disease. The aim of this study was to review the literature regarding the different types of dietary supplementations and their effectiveness in the management of ATDs.Methods: Using a predefined search strategy, four databases were searched (PubMed,...

IntroductionPrediabetes and type 2 diabetes prevalence in children and teenagers has been rising lately, according to obesity increase in this population. Diabetes is the first cause of kidney failure in this individuals. These clinical entities are associated with hypertension and dyslipidemia, leading to an increased risk for cardiovascular disease. In this case, as a result of the presence of a diabetic complication, the differential diagnosis of the ...

Paltusotine is an investigational oral, once-daily, non-peptide, SST2 agonist in development for the treatment of acromegaly and neuroendocrine tumors. Interim analysis results from subjects with acromegaly treated with paltusotine for up to 2 years in ACROBAT Advance (NCT04261712), an ongoing, open-label extension study are reported here. Prior to Advance, subjects previously completed one of two Phase 2 parent studies, Evolve (NCT03792555, with normal IGF-1 using injected lo...